HeyHippocratesAF, ACS, heart failure — a colleague who cites every call.
Clinical decision support that reasons like a cardiologist while you decide: score the stroke risk, risk-stratify the chest pain, build the GDMT — with the decision rule and exactly what would change it. Built for verified cardiologists.
Watch it think — in cardiology.
Two worked examples, reasoned the way it answers: the relevant clinical checks run, the answer is cited, the decision rule is explicit, and what is missing is flagged.
58-year-old, 40 min of crushing chest pain, ECG ST-depression in V4–V6, first troponin rising — STEMI or NSTEMI, and what now?
ST-depression with a rising troponin and no persistent ST-elevation is NSTE-ACS (NSTEMI). Load dual antiplatelet + anticoagulation and risk-stratify with GRACE: a high score (>140) or ongoing ischemia favors an early invasive strategy (angiography <24 h). Persistent ST-elevation would instead trigger primary PCI within 90 minutes.
Decision ruleNo persistent ST-elevation → NSTE-ACS: DAPT + anticoagulation, GRACE-based timing (>140 → invasive <24 h); persistent ST-elevation → primary PCI <90 min.
Not established from this alone — the full 12-lead, serial troponin, hemodynamics and bleeding risk change the strategy and timing.
72-year-old woman, new atrial fibrillation, hypertension and type-2 diabetes — anticoagulate, and rate or rhythm control?
CHA₂DS₂-VASc here is at least 4 (age 65–74 = 1, female = 1, hypertension = 1, diabetes = 1) — well above the threshold, so oral anticoagulation with a DOAC is indicated. For most, start rate control with a β-blocker and decide rhythm control by symptoms; early rhythm control is reasonable in recent-onset AF.
Decision ruleCHA₂DS₂-VASc ≥2 (men) / ≥3 (women) → anticoagulate, DOAC preferred over warfarin; rate control first-line, rhythm control for symptoms or early AF.
Not established from this alone — exact age, bleeding risk (HAS-BLED), renal function and symptom burden refine both decisions.
Illustrative simulations. The physician always decides.
The answers cardiologists actually look up.
The exact questions your field searches for — answered in the format the knowledge base speaks: the answer, the decision rule, what's missing, and the source.
CHA₂DS₂-VASc — should I anticoagulate this AF patient?
CHA₂DS₂-VASc scores stroke risk in non-valvular AF: CHF (1), hypertension (1), age ≥75 (2), diabetes (1), prior stroke/TIA/thromboembolism (2), vascular disease (1), age 65–74 (1), female sex (1). A DOAC is preferred over warfarin for most; the sex point alone does not mandate anticoagulation.ESC AF · CHA₂DS₂-VASc
Decision ruleScore ≥2 (men) or ≥3 (women) → oral anticoagulation, DOAC preferred; 1 (men) / 2 (women) → consider; 0 / 1 → none.
Missing data: valvular status (a mechanical valve or moderate–severe mitral stenosis needs warfarin), bleeding risk and renal function change the choice.
Acute coronary syndrome — STEMI vs NSTEMI, and the first-hour priorities?
Persistent ST-elevation (or new LBBB) with symptoms is STEMI → immediate reperfusion, primary PCI within 90 minutes (fibrinolysis if PCI is not timely). Without persistent ST-elevation it is NSTE-ACS → dual antiplatelet + anticoagulation and GRACE-based timing of invasive angiography. A rising troponin distinguishes NSTEMI from unstable angina.ESC ACS guideline
Decision ruleST-elevation → primary PCI <90 min; no ST-elevation → NSTE-ACS pathway, GRACE >140 or refractory ischemia → invasive <24 h.
Missing data: the 12-lead evolution, troponin kinetics, hemodynamic status and bleeding risk drive reperfusion and antithrombotic choice.
Heart failure — the four pillars of GDMT for HFrEF?
For HFrEF (LVEF ≤40%) start all four pillars early and titrate: an ARNI (or ACE-inhibitor/ARB), a β-blocker, an MRA, and an SGLT2 inhibitor. Each independently reduces mortality and hospitalization; add a loop diuretic for congestion only. NYHA class tracks symptoms and guides device and advanced-therapy referral.ESC/ACC HF guideline
Decision ruleHFrEF → the four pillars (ARNI/ACEi, β-blocker, MRA, SGLT2i), titrated to target; diuretics for symptoms; reassess LVEF before ICD/CRT.
Missing data: LVEF, blood pressure, potassium and renal function, and NYHA class set the sequence and titration pace.
Atrial fibrillation — rate or rhythm control?
Anticoagulation is decided independently of the rhythm strategy. Rate control (a β-blocker or non-dihydropyridine calcium blocker, resting target <110 initially) suits many. Rhythm control — antiarrhythmics or catheter ablation — is favored for persistent symptoms, recent-onset AF, heart failure or younger patients; early rhythm control improves outcomes in recently diagnosed AF.ESC AF guideline
Decision ruleAnticoagulate by CHA₂DS₂-VASc regardless of strategy; rate control first-line; rhythm control for symptoms, early AF or HF — ablation if drugs fail.
Missing data: symptom burden, AF duration, LV function and left-atrial size shift the balance toward rhythm control or ablation.
What it knows in cardiology
Your whole practice, one specialist brain — grounded in specialist-written, cited knowledge.
A generalist cardiology colleague across heart failure, arrhythmia, coronary disease, valvular disease and prevention — cited, non-directive, always with the decision rule.
Deep specialist agents for interventional, electrophysiology, heart-failure & transplant and cardiac imaging — each its own specialist voice and knowledge base — plus your own uploaded materials.
Why not just use OpenEvidence or ChatGPT?
A large language model answers any clinical question with total confidence and no idea whether it is right. A search engine finds papers. HeyHippocrates reasons inside your specialty from a knowledge base a specialist in your field wrote and signed, and tells you the decision rule and what is missing.
Be one of the first cardiologists in.
The waitlist is a founding cohort: 40 specialties in build, neurosurgery opens first, and your specialty’s waitlist decides what opens next.
- 1 free month — the whole product, no card.
- Then 50% off for three months.
- A numbered Founding Cardiologist badge.
- First say on what your specialty gets next.
Join the cardiology waitlist
Leave your name and work email. We'll reach out the moment cardiology opens — with your Founding Cardiologist offer.
One email at launch. No spam, ever.
Questions cardiologists ask
It works in the scores you use — CHA₂DS₂-VASc for stroke risk and HAS-BLED for bleeding — and always shows the reasoning behind the score, the anticoagulation threshold, and what would change it. The decision always stays your call.
Both. Fellows use it to pressure-test a plan and learn the decision rule; attendings use it as a fast, cited second opinion between cases. Access is gated to verified physicians.
Interventional, electrophysiology, heart-failure & transplant, and cardiac imaging each have their own deep specialist agent on the Pro plan, on top of the full general-cardiology scope on Basic.
No. It is physician-facing clinical decision support — a cited thinking partner. It does not diagnose, does not treat, and gives no patient-facing advice. The decision always stays with you.
Every answer is grounded only in specialist-written, cited cardiology knowledge — traceable to a named source — and always states the decision rule plus what data is missing, instead of a confident guess.